Gubra A/S (GUBRA) - Total Assets
Based on the latest financial reports, Gubra A/S (GUBRA) holds total assets worth Dkr1.32 Billion DKK (≈ $206.50 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Gubra A/S - Total Assets Trend (2019–2025)
This chart illustrates how Gubra A/S's total assets have evolved over time, based on quarterly financial data. Also see GUBRA stock market capitalisation for the company's overall valuation and market capitalisation.
Gubra A/S - Asset Composition Analysis
Current Asset Composition (December 2025)
Gubra A/S's total assets of Dkr1.32 Billion consist of 87.9% current assets and 12.1% non-current assets. Review Gubra A/S balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 2.4% |
| Accounts Receivable | Dkr72.59 Million | 5.5% |
| Inventory | Dkr0.00 | 0.0% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr13.22 Million | 1.0% |
| Goodwill | Dkr0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Gubra A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Gubra A/S stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gubra A/S's current assets represent 87.9% of total assets in 2025, an increase from 52.7% in 2019.
- Cash Position: Cash and equivalents constituted 2.4% of total assets in 2025, down from 23.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 5.5% of total assets.
Gubra A/S Competitors by Total Assets
Key competitors of Gubra A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥729.16 Million |
|
Pulike Biological Engineering
SHG:603566
|
China | CN¥3.09 Billion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $423.10 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
Gubra A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.63 | 6.06 | 1.87 |
| Quick Ratio | 13.63 | 6.06 | 1.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr1.08 Billion | Dkr401.70 Million | Dkr54.41 Million |
Gubra A/S - Advanced Valuation Insights
This section examines the relationship between Gubra A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.61 |
| Latest Market Cap to Assets Ratio | 0.59 |
| Asset Growth Rate (YoY) | 115.5% |
| Total Assets | Dkr1.32 Billion |
| Market Capitalization | $777.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Gubra A/S's assets below their book value (0.59x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Gubra A/S's assets grew by 115.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Gubra A/S (2019–2025)
The table below shows the annual total assets of Gubra A/S from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr1.32 Billion ≈ $206.50 Million |
+115.49% |
| 2024-12-31 | Dkr612.48 Million ≈ $95.83 Million |
-2.05% |
| 2023-12-31 | Dkr625.28 Million ≈ $97.83 Million |
+137.84% |
| 2022-12-31 | Dkr262.90 Million ≈ $41.13 Million |
-12.98% |
| 2021-12-31 | Dkr302.12 Million ≈ $47.27 Million |
+54.80% |
| 2020-12-31 | Dkr195.17 Million ≈ $30.54 Million |
+14.75% |
| 2019-12-31 | Dkr170.08 Million ≈ $26.61 Million |
-- |
About Gubra A/S
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for th… Read more